Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M MacDonald

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Pharmacoepidemiology and Drug Safety|January 2, 2021
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysisDaniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, et al.
JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
Atherosclerosis. Supplements|February 16, 2021
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 studyJacek J Jóźwiak, Krzysztof Studziński, Tomasz Tomasik, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Rheumatology International|November 10, 2021
Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional studyPaweł Krzemień, Sławomir Kasperczyk, Maciej Banach, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Archives of Medical Science : AMS|September 21, 2023
Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studiesPaweł Krzemień, Sławomir Kasperczyk, Maciej Banach, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Biomarker Insights|February 7, 2022
Relationship Between Anti-DFS70 Autoantibodies and Oxidative StressPaweł Krzemień, Sławomir Kasperczyk, Maciej Banach, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Pharmacoepidemiology and Drug Safety|January 2, 2021
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysisDaniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, et al.
JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
Atherosclerosis. Supplements|February 16, 2021
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 studyJacek J Jóźwiak, Krzysztof Studziński, Tomasz Tomasik, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Rheumatology International|November 10, 2021
Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional studyPaweł Krzemień, Sławomir Kasperczyk, Maciej Banach, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Archives of Medical Science : AMS|September 21, 2023
Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studiesPaweł Krzemień, Sławomir Kasperczyk, Maciej Banach, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Biomarker Insights|February 7, 2022
Relationship Between Anti-DFS70 Autoantibodies and Oxidative StressPaweł Krzemień, Sławomir Kasperczyk, Maciej Banach, et al.
Pageof 16